A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR1501 Injection by in Patients With Active Axial Spondyloarthritis
Latest Information Update: 07 Apr 2023
At a glance
- Drugs Xeligekimab (Primary)
- Indications Axial spondyloarthritis
- Focus Therapeutic Use
- Sponsors Genrix (Shanghai) Biopharmaceuticals
- 21 Mar 2023 Status changed from active, no longer recruiting to completed.
- 23 Dec 2021 New trial record